Psychotic Disorders Program, UMass Memorial Medical Center, Worcester, MA, USA.
J Clin Psychopharmacol. 2013 Apr;33(2):226-30. doi: 10.1097/JCP.0b013e31828701d0.
This study examined the effect of adjunctive intranasal insulin therapy on psychopathology and cognition in patients with schizophrenia.
Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder and been on stable antipsychotics for at least 1 month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale and the Scale for Assessment of Negative Symptoms. A neuropsychological battery was used to assess cognitive performance. The assessment for psychopathology and cognition was conducted at baseline, week 4, and week 8.
A total of 45 subjects were enrolled in the study (21 in the insulin group and 24 in the placebo group). The mixed model analysis showed that there were no significant differences between the 2 groups at week 8 on various psychopathology and cognitive measures (P > 0.1).
Adjunctive therapy with intranasal insulin did not seem to be beneficial in improving schizophrenia symptoms or cognition in the present study. The implications for future studies were discussed.
本研究旨在探讨辅助鼻腔内给予胰岛素治疗对精神分裂症患者精神病理学和认知功能的影响。
每位受试者均符合《精神障碍诊断与统计手册》第 4 版（DSM-IV）精神分裂症或分裂情感性障碍的诊断标准，且至少在 1 个月前开始接受稳定的抗精神病药物治疗。在一项为期 8 周的随机、双盲、安慰剂对照研究中，受试者接受鼻腔内胰岛素（40IU，每日 4 次）或安慰剂治疗。使用阳性和阴性综合征量表（PANSS）和阴性症状评定量表（SANS）评估精神病理学。使用神经心理学成套测验评估认知功能。在基线、第 4 周和第 8 周进行精神病理学和认知评估。
共有 45 名受试者入组（胰岛素组 21 例，安慰剂组 24 例）。混合模型分析显示，在第 8 周时，2 组在各种精神病理学和认知测量指标上均无显著差异（P＞0.1）。
在本研究中，辅助鼻腔内给予胰岛素治疗似乎对改善精神分裂症症状或认知功能无明显益处。讨论了对未来研究的启示。
